Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone for Recurrent Neuromyelitis Optica
NCT00304291Phase 4Completed
- Sponsor
- University at Buffalo
- Start
- Aug 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone in neuromyelitis optica (NMO), sponsored by University at Buffalo. Primary endpoint: Relapse rate at 24 months. Started Aug 2001; status: completed.
02
Drugs
mitoxantrone
03
Conditions
neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT00304291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304291.